In other Viking Therapeutics news, CEO Brian Lian sold 194,490 shares of Viking Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $42.75 ...

Viking Therapeutics (NASDAQ:VKTX – Free Report) had its target price lowered by Maxim Group from $120.00 to $70.00 in a research note issued to investors on Friday morning,Benzinga reports.

Nearly a year ago, Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss ...

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year. Viking Therapeutics is developing a drug that might be able to outperform today's most popular ...

Truist lowered the firm’s price target on Viking Therapeutics (VKTX) to $95 from $120 and keeps a Buy rating on the shares. The company’s Q4 update narrowed the timeline for the start of two ...

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains a buyer on share weakness following the Q4 report.